The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its…
After an amazing day in Paris for Labiotech Refresh, we head back to Germany to…
GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down…
Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer's,…
A Migraine is more than just a headache; it is a neurological disorder affecting a…
Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for…
The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up…
You must have heard of GPCRs, or more specifically G protein-coupled receptors. Doesn’t ring a…
Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration…
Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody…